Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis

Recruiting

UblituximabUblituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis

Sponsor:

Northwestern University

Code:

NCT07225361

Conditions

Multiple Sclerosis

Multiple Sclerosis (MS) - Relapsing-remitting

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Not accepted

Interventions

Ublituximab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-01-08. This information was provided to ClinicalTrials.gov by Northwestern University on 2025-12-24.